JCR Stock Overview

Engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. More details

JCR fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	0/6
Financial Health	3/6
Dividends	3/6

Rewards

Trading at 37.5% below our estimate of its fair value

Earnings are forecast to grow 24.27% per year

Risk Analysis

Dividend of 3.77% is not well covered by earnings or free cash flows

Volatile share price over the past 3 months compared to the German market

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

My Notes

Capture your thoughts, links and company narrative

JCR Pharmaceuticals Co., Ltd. Competitors

PharmaSGP Holding

XTRA:PSG

€321.3m

Apontis Pharma

XTRA:APPH

€91.6m

Dermapharm Holding

XTRA:DMP

€2.1b

Cantourage Group

XTRA:HIGH

€58.9m

Price History & Performance

Summary of share price highs, lows and changes for JCR Pharmaceuticals
Historical stock prices
Current Share Price	JP¥3.32
52 Week High	JP¥4.62
52 Week Low	JP¥2.98
Beta	0.042
1 Month Change	1.84%
3 Month Change	-23.85%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-17.41%

Recent updates

Shareholder Returns

	JCR	DE Pharmaceuticals	DE Market
7D	7.8%	-0.2%	-1.3%
1Y	n/a	-16.2%	14.9%

Return vs Industry: Insufficient data to determine how JCR performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how JCR performed against the German Market.

Price Volatility

Is JCR's price volatile compared to industry and market?
JCR volatility
JCR Average Weekly Movement	7.6%
Pharmaceuticals Industry Average Movement	4.1%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.6%
10% least volatile stocks in DE Market	2.5%

Stable Share Price: JCR's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine JCR's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1975	934	Shin Ashida	www.jcrpharm.co.jp

JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease.

JCR Pharmaceuticals Co., Ltd. Fundamentals Summary

How do JCR Pharmaceuticals's earnings and revenue compare to its market cap?
JCR fundamental statistics
Market cap	€410.83m
Earnings (TTM)	-€1.46m
Revenue (TTM)	€222.91m

1.8x

P/S Ratio

-282.0x

P/E Ratio

Is JCR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
JCR income statement (TTM)
Revenue	JP¥35.03b
Cost of Revenue	JP¥10.20b
Gross Profit	JP¥24.83b
Other Expenses	JP¥25.06b
Earnings	-JP¥229.00m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.88
Gross Margin	70.87%
Net Profit Margin	-0.65%
Debt/Equity Ratio	61.2%

How did JCR perform over the long term?

See historical performance and comparison

Dividends

3.8%

Current Dividend Yield

-1,087%

Payout Ratio

Does JCR pay a reliable dividends?

See JCR dividend history and benchmarks

When do you need to buy JCR by to receive an upcoming dividend?
JCR Pharmaceuticals dividend dates
Ex Dividend Date	Mar 28 2025
Dividend Pay Date	Jun 27 2025
Days until Ex dividend	34 days
Days until Dividend pay date	125 days

Does JCR pay a reliable dividends?

See JCR dividend history and benchmarks

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/20 15:21
End of Day Share Price	2025/02/20 00:00
Earnings	2024/12/31
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

JCR Pharmaceuticals Co., Ltd. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Tatsuyuki Arai	BofA Global Research
Hidemaru Yamaguchi	Citigroup Inc
Kazuaki Hashiguchi	Daiwa Securities Co. Ltd.